Quarterly Result27 May 2026, 06:52 pm
Bal Pharma: FY26 Audited Results, Dividend of ₹1.20 Recommended
AI Summary
Bal Pharma Ltd. announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board recommended a dividend of ₹1.20 per equity share (12%), subject to shareholder approval. They also approved the grant of 5,00,000 stock options to employees and a preferential issue of 10,00,000 warrants to promoters. Additionally, Murugesh & Co was appointed as Internal Auditors and G.N.V & Associates as Cost Auditors for FY 2025-26. Mr. Shreepada ML was appointed as Company Secretary and Compliance Officer.
Key Highlights
- Audited financial results for FY26 approved with unmodified opinion.
- Dividend of ₹1.20 per share (12%) recommended, pending shareholder approval.
- 5,00,000 stock options granted to employees under ESOP 2025.
- Preferential issue of 10,00,000 warrants to promoters approved.
- Mr. Shreepada ML appointed as Company Secretary and Compliance Officer.
Price Impact
More from BALPHARMA